Disease-regulated gene therapy for arthritic diseases. From experimental arthritis to human in vitro models
Publication year
2017Author(s)
Annotation
Radboud University, 03 oktober 2017
Promotor : Berg, W.B. van den Co-promotores : Loo, F.A.J. van de, Thurlings, R.M.
Publication type
Dissertation
Display more detailsDisplay less details
Organization
Rheumatology
Subject
Radboud Institute for Molecular Life Sciences; Radboudumc 5: Inflammatory diseases; Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life SciencesAbstract
A modern treatment for rheumatoid arthritis often consists of the administration of so-called ‚biologics‘. These are protein-based drugs, which are often administered by weekly injections to suppress the immune system. Although they work well for many patients, the continuous immune suppression can also lead to side effects. Mathijs Broeren investigated a modern strategy to provide the blueprints (genes) of the biologic proteins to the cells from an arthritic joint. By allowing the cells to produce the biologics, only the diseased joint is exposed to the medication and patients do not require regular injections. In addition, a disease-sensitive switch (promoter) can be incorporated in the blueprint, which causes the cells to only produce the medicine during active arthritis. Using this treatment, the inflammatory reaction could be suppressed in micromasses, an advanced 3-dimensional model of a human joint. In the coming years, this therapy can be further developed to eventually be applied in rheumatoid arthritis patients.
This item appears in the following Collection(s)
- Academic publications [238586]
- Dissertations [13460]
- Electronic publications [122848]
- Faculty of Medical Sciences [90409]
- Open Access publications [97830]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.